Dedicated to Discovery. Committed to Care.

Paths of Progress

Spring/Summer 2007 Paths of Progress

A hydrocarbon “staple” at right stabilizes a mini-protein, illustrated here as ribbon and mesh.
(Courtesy of Peter Kutchukian and Eric Smith)

Spring/Summer 2007
Volume 16, Number 1

Contents

Features

  • Divide and conquer
    By Richard Saltus

    Sorting lymphomas by their genetic signatures allows investigators to better target existing therapies or develop new ones needed to fight this varied group of cancers.

  • The power of two
    By Robert Levy

    The Dana-Farber/Harvard Cancer Center and University of Massachusetts Boston are working to train minority nurses and reduce disparities in oncology awareness and treatment.

  • Molecular engineers
    By Robert Levy

    Using advanced technology to build compounds from small molecules, chemical biologists are studying the genetic precursors for cancer and designing strategies to thwart them.

  • Special bonds
    By Saul Wisnia

    As more children with cancer survive to adulthood, they are forging close ties with their caregivers while also educating them about aftereffects of pediatric treatment.

  • First Person: Evie Goldfine
    Edited by Christine Cleary

    Through wise, witty, and poignant entries from her blog, lymphoma survivor Evie Goldfine discusses her encounters with cancer and reflects on loved ones lost.

  • A father's illness, a son's quest
    LeviGarraway, MD, PhD

Departments

Correction about breast cancer study

A story in the last issue of Paths of Progress about the Study of Tamoxifen and Raloxifene (STAR) should have stated that the drug raloxifene reduces the chances of breast cancer occurrence (not recurrence) in postmenopausal women at increased risk for the disease. Please note that raloxifene is used to treat osteoporosis, not breast cancer. For more information about the STAR trial and other ongoing breast cancer risk-reduction studies at Dana-Farber, visit www.dana-farber.org/pat/cancer/default.html.

Credits

President, Dana-Farber Cancer Institute Edward J. Benz Jr., MD
Chief of Staff Stephen E. Sallan, MD
Chief Medical Officer Lawrence N. Shulman, MD
Chief Scientific Officer Barrett J. Rollins, MD
Chief Clinical Officer Philip W. Kantoff, MD
Chair, Medical Oncology James D. Griffin, MD
Chair, Pediatric Oncology Stuart H. Orkin, MD
Chair, Radiation Oncology Jay R. Harris, MD
Chair (Acting), Executive Committee for Research David M. Livingston, MD
Senior VP for Experimental Medicine Lee M. Nadler, MD
Senior VP for Patient Care Services, Chief Nurse Patricia Reid Ponte, RN, DNSc, FAAN
Senior VP for Research Beverly R. Ginsburg, MBA

Senior VP for Communications Steven R. Singer
Director of Publications Paul Hennessy
Editor Debra Ruder
Design/Production John DiGianni
Associate Editor Robert Levy
Articles Editor Saul Wisnia
Staff Writers Christine Cleary, Richard Saltus
Production Assistance Nicole Bedard, Patricia Cleary, Kathleen Raven, Kim Regensburg, Irina Zlobina
Photography Sam Ogden, Shawn Henry (pp. 29-30)

Paths of Progress is published twice a year by Dana-Farber Cancer Institute's Department of Communications. If you have any comments or would like to be removed from the mailing list, contact:

Debra Ruder
Editor, Paths of Progress
Dana-Farber Cancer Institute, Department of Communications
44 Binney Street
Boston, MA 02115

(617) 632-4090
debra_ruder@dfci.harvard.edu

Copyright © 2007 Dana-Farber Cancer Institute. All rights reserved.

Paths of Progress Archive

History of advances

From achieving the first remissions of ALL and Wilm's tumor in pediatric patients in the '40s and '50s, to the development of Gleevec, the first "smart" cancer drug, in the late '90s, Dana-Farber researchers and clinicians have been at the forefront of discovery in cancer care and research. learn more